Evidence map›Paper›PMID 31267207›Full record

ArticleJournal of neurology2019

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Daniele Altomare, Clarissa Ferrari, Anna Caroli, Samantha Galluzzi, Annapaola Prestia, Wiesje M van der Flier, Rik Ossenkoppele, Bart Van Berckel, Frederik Barkhof, Charlotte E Teunissen and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniele AltomareLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-1905-8993
Clarissa FerrariService of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni 4, 25125, Brescia, Italy. cferrari@fatebenefratelli.eu.ORCID http://orcid.org/0000-0002-4101-6872
Anna CaroliMedical Imaging Unit, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.ORCID https://orcid.org/0000-0002-4130-4663
Samantha GalluzziLaboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Annapaola PrestiaLaboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Wiesje M van der FlierAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Rik OssenkoppeleAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Bart Van BerckelAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-3543-3706
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Anders WallSection of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Stephen F CarterAlzheimer Neurobiology Center, Karolinska Institutet, Stockholm, Sweden.
Michael SchöllClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.
I L Han ChooAlzheimer Neurobiology Center, Karolinska Institutet, Stockholm, Sweden.
Timo GrimmerDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Alberto RedolfiLaboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Agneta NordbergCenter for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Philip ScheltensAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Alexander DrzezgaDepartment of Nuclear Medicine, University of Cologne, Cologne, Germany.
Giovanni B FrisoniLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-6419-1753
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Alzheimer's Disease Neuroimaging Initiative National Institutes of Health Grant U01 AG024904DOD ADNI Department of Defense award number W81XWH-12-2-0012European Union Seventh Framework Programme (FP7/2007-2013) grant agreement number 283562Swedish Research Council 'Strategy Research Program in Neuroscience at Karolinska Institutes, the Swedish Brain Power project 05817
6 · The paper itself

Abstract

objectiveThe aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).

methodsWe measured Aβ42, t-tau, hippocampal volume on magnetic resonance imaging (MRI) and cortical metabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET) in 188 MCI patients followed for at least 1 year. We categorised patients into earlier and later onset (EO/LO). Receiver operating characteristic curves and corresponding areas under the curve (AUCs) were performed to assess and compar the biomarker prognostic performances in EO and LO groups. Linear Model was adopted for estimating the time-to-progression in relation with earlier/later onset MCI groups and biomarkers.

resultsIn earlier onset patients, all the assessed biomarkers were able to predict cognitive decline (p < 0.05), with FDG-PET showing the best performance. In later onset patients, all biomarkers but t-tau predicted cognitive decline (p < 0.05). Moreover, FDG-PET alone in earlier onset patients showed a higher prognostic value than the one resulting from the combination of all the biomarkers in later onset patients (earlier onset AUC 0.935 vs later onset AUC 0.753, p < 0.001). Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease. DISCUSSION: FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients and may be used for obtaining an onset-related estimate of the time free from disease.

Indexed as

Cerebral CortexDisease ProgressionAgedAged, 80 and overAge of OnsetAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionDatasets as TopicFemaleFluorodeoxyglucose F18Follow-Up StudiesHippocampusHumansMagnetic Resonance ImagingAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersFluorodeoxyglucose F18Peptide Fragmentstau ProteinsAlzheimerBiomarkersCognitionFDG-PETImaging

Identifiers

PMID31267207

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.